×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| FABINO ENTERPRISES LIMITED | NA | NA | NA | NA | 5.46 | 91.0 |
| Triochem Products Ltd., | NA | NA | NA | NA | 0 | |
| MARKSANS PHARMA LTD. | 3217.44 | 480.56 | 3197.34 | 1.06 | 7,790 | 22.2 |
| YATHARTH HOSPITAL & TRAUMA CAR | 1374.03 | 271.22 | 1301.44 | 2.81 | 7583 | 53.3 |
| FDC LTD. | 6778.67 | 1221.91 | 6422.81 | 7.51 | 7444 | 27.7 |
Marksans Pharma Ltd., with Security Code 524404, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 153.0 | 182.0 | 204.7 | 241.4 | 225.2 | 254.5 | 308.6 | 311.9 | 299.4 | 319.7 |
| Expenses | 130.3 | 155.3 | 167.4 | 199.4 | 191.3 | 213.3 | 256.4 | 251.9 | 248.7 | 249.7 |
| Operating Profit | 22.7 | 26.8 | 37.3 | 42.0 | 33.9 | 41.3 | 52.3 | 59.9 | 50.6 | 70.1 |
| OPM % | 14.84% | 14.7% | 18.22% | 17.39% | 15.06% | 16.21% | 16.94% | 19.22% | 16.92% | 21.91% |
| Other Income | 4.3 | 32.6 | 15.9 | 1.3 | 12.2 | 8.2 | 31.4 | 22.5 | 7.8 | 2.0 |
| Interest | 0.7 | 0.3 | 0.2 | 0.3 | 0.2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 |
| Depreciation | 3.5 | 4.7 | 8.5 | 8.4 | 7.5 | 6.8 | 7.0 | 7.4 | 8.2 | 8.2 |
| Profit before tax | 22.8 | 54.4 | 44.5 | 34.6 | 38.4 | 42.3 | 76.3 | 74.7 | 50.0 | 63.6 |
| Tax % | -22% | -18.8% | -29.7% | -26.9% | -14.1% | 24.3% | -17.2% | -25.8% | -24.6% | 24.4% |
| Net Profit | 17.8 | 44.2 | 31.3 | 25.3 | 33.0 | 32.0 | 63.2 | 55.5 | 37.6 | 48.1 |
| EPS in Rs | 0.43 | 0.98 | 0.69 | 0.56 | 0.73 | 0.71 | 1.39 | 1.22 | 0 | 1.06 |
| Metrics | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 479.8 | 486.0 | 500.0 | 531.2 | 586.1 | 560.0 | 590.6 | 641.9 | 681.8 | 70.8 |
| Expenses | 403.2 | 376.4 | 398.1 | 417.3 | 453.1 | 450.4 | 462.2 | 506.2 | 543.1 | 58.2 |
| Operating Profit | 76.6 | 109.5 | 102.0 | 113.9 | 133.0 | 109.6 | 128.4 | 135.7 | 138.8 | 12.7 |
| OPM % | 15.97% | 22.54% | 20.39% | 21.45% | 22.7% | 19.58% | 21.75% | 21.14% | 20.35% | 17.88% |
| Other Income | 17.7 | 11.0 | 10.1 | 19.0 | 4.8 | 16.5 | 14.9 | 11.1 | 27.8 | 1.7 |
| Interest | 2.4 | 2.4 | 1.6 | 1.6 | 3.2 | 4.8 | 2.9 | 2.6 | 2.7 | 0.3 |
| Depreciation | 12.7 | 13.9 | 13.7 | 17.6 | 22.0 | 21.1 | 20.4 | 19.5 | 20.7 | 2.3 |
| Profit before tax | 79.2 | 104.2 | 96.8 | 113.8 | 112.7 | 100.3 | 120.0 | 124.6 | 143.3 | 11.7 |
| Tax % | -21.3% | -20.6% | -27.3% | -26.3% | -26.4% | -22.6% | -25.8% | 21.5% | 26.7% | -21.5% |
| Net Profit | 62.3 | 82.7 | 70.4 | 83.9 | 83.0 | 77.6 | 89.1 | 97.8 | 105.1 | 9.1 |
| EPS in Rs | 1.56 | 1.97 | 1.52 | 1.84 | 1.84 | 1.73 | 1.96 | 2.13 | 2.31 | 0 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 22% |
| 3 Years: | 21% |
| TTM: | 38% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 38% |
| 3 Years: | 22% |
| TTM: | 41% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 66% |
| 3 Years: | 72% |
| 1 Year: | 46% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 18% |
| 3 Years: | 21% |
| TTM: | 20% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 26% |
| 3 Years: | 27% |
| TTM: | 21% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 66% |
| 3 Years: | 72% |
| 1 Year: | 46% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Acq. Mode
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|
| Period | SMA Value | Status |
|---|
| Period | EMA Value | Status |
|---|
| Indicator | Value |
|---|